Therapeutic approaches using nitric oxide in infants and children

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pulmonary hypertension contributes significantly to the morbidity and mortality associated with many pediatric pulmonary and cardiac diseases. Nitric oxide, a gas molecule, is a unique pharmaceutical agent that can be inhaled and thus delivered directly to the lung. Inhaled nitric oxide was approved by the FDA in 1999 as a therapy for infants with persistent pulmonary hypertension. Since then, the use of inhaled nitric oxide has expanded to other neonatal and pediatric conditions, and our knowledge of its properties and mechanisms of action has increased tremendously. This review discusses the physiology of nitric oxide signaling, the most common indications for its clinical use, and promising new investigations that may enhance endogenous production of nitric oxide and/or improve vascular response to it.

Original languageEnglish (US)
Pages (from-to)1027-1034
Number of pages8
JournalFree Radical Biology and Medicine
Volume51
Issue number5
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Nitric Oxide
Pediatrics
Pulmonary Hypertension
Therapeutics
Physiology
Lung Diseases
Blood Vessels
Heart Diseases
Gases
Morbidity
Lung
Molecules
Mortality
Pharmaceutical Preparations

Keywords

  • cGMP
  • Congenital heart disease
  • Free radicals
  • Neonate
  • Nitric oxide
  • Nitric oxide synthase
  • Pulmonary hypertension
  • Reactive oxygen species

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

Therapeutic approaches using nitric oxide in infants and children. / Steinhorn, Robin H.

In: Free Radical Biology and Medicine, Vol. 51, No. 5, 01.09.2011, p. 1027-1034.

Research output: Contribution to journalArticle

@article{391f1d68c1e54a388ff6aa87bf431bfb,
title = "Therapeutic approaches using nitric oxide in infants and children",
abstract = "Pulmonary hypertension contributes significantly to the morbidity and mortality associated with many pediatric pulmonary and cardiac diseases. Nitric oxide, a gas molecule, is a unique pharmaceutical agent that can be inhaled and thus delivered directly to the lung. Inhaled nitric oxide was approved by the FDA in 1999 as a therapy for infants with persistent pulmonary hypertension. Since then, the use of inhaled nitric oxide has expanded to other neonatal and pediatric conditions, and our knowledge of its properties and mechanisms of action has increased tremendously. This review discusses the physiology of nitric oxide signaling, the most common indications for its clinical use, and promising new investigations that may enhance endogenous production of nitric oxide and/or improve vascular response to it.",
keywords = "cGMP, Congenital heart disease, Free radicals, Neonate, Nitric oxide, Nitric oxide synthase, Pulmonary hypertension, Reactive oxygen species",
author = "Steinhorn, {Robin H}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.freeradbiomed.2011.01.006",
language = "English (US)",
volume = "51",
pages = "1027--1034",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Therapeutic approaches using nitric oxide in infants and children

AU - Steinhorn, Robin H

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Pulmonary hypertension contributes significantly to the morbidity and mortality associated with many pediatric pulmonary and cardiac diseases. Nitric oxide, a gas molecule, is a unique pharmaceutical agent that can be inhaled and thus delivered directly to the lung. Inhaled nitric oxide was approved by the FDA in 1999 as a therapy for infants with persistent pulmonary hypertension. Since then, the use of inhaled nitric oxide has expanded to other neonatal and pediatric conditions, and our knowledge of its properties and mechanisms of action has increased tremendously. This review discusses the physiology of nitric oxide signaling, the most common indications for its clinical use, and promising new investigations that may enhance endogenous production of nitric oxide and/or improve vascular response to it.

AB - Pulmonary hypertension contributes significantly to the morbidity and mortality associated with many pediatric pulmonary and cardiac diseases. Nitric oxide, a gas molecule, is a unique pharmaceutical agent that can be inhaled and thus delivered directly to the lung. Inhaled nitric oxide was approved by the FDA in 1999 as a therapy for infants with persistent pulmonary hypertension. Since then, the use of inhaled nitric oxide has expanded to other neonatal and pediatric conditions, and our knowledge of its properties and mechanisms of action has increased tremendously. This review discusses the physiology of nitric oxide signaling, the most common indications for its clinical use, and promising new investigations that may enhance endogenous production of nitric oxide and/or improve vascular response to it.

KW - cGMP

KW - Congenital heart disease

KW - Free radicals

KW - Neonate

KW - Nitric oxide

KW - Nitric oxide synthase

KW - Pulmonary hypertension

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=79961044260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961044260&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2011.01.006

DO - 10.1016/j.freeradbiomed.2011.01.006

M3 - Article

VL - 51

SP - 1027

EP - 1034

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

IS - 5

ER -